[1]
|
Vitale, I., Manic, G., Coussens, L.M., et al. (2019) Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 30, 36-50. https://doi.org/10.1016/j.cmet.2019.06.001
|
[2]
|
Jin, M.Z. and Jin, W.L. (2020) The Updated Landscape of Tumor Microenvironment and Drug Repurposing. Signal Transduction and Targeted Therapy, 5, Article No. 166. https://doi.org/10.1038/s41392-020-00280-x
|
[3]
|
So, J.Y., Ohm, J., Lipkowitz, S. and Yang, L. (2022) Triple Negative Breast Cancer (TNBC): Non-Genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Options. Pharmacology & Therapeutics, 237, Article ID: 108253. https://doi.org/10.1016/j.pharmthera.2022.108253
|
[4]
|
Underwood, J.C. (1974) Lymphoreticular Infiltration in Human Tumours: Prognostic and Biological Implications: A Review. British Journal of Cancer, 30, 538-548. https://doi.org/10.1038/bjc.1974.233
|
[5]
|
Salgado, R., Denkert, C., Demaria, S., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26, 259-271. https://doi.org/10.1093/annonc/mdu450
|
[6]
|
Denkert, C., Von Minckwitz, G., Darb-Esfahani, S., et al. (2018) Tumour-Infiltrating Lymphocytes and Prognosis in Different Subtypes of Breast Cancer: A Pooled Analysis of 3771 Patients Treated with Neoadjuvant Therapy. The Lancet Oncology, 19, 40-50. https://doi.org/10.1016/S1470-2045(17)30904-X
|
[7]
|
Broglio, K.R., Quintana, M., Foster, M., et al. (2016) Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer with Long-Term Outcomes: A Meta-Analysis. JAMA Oncology, 2, 751-760. https://doi.org/10.1001/jamaoncol.2015.6113
|
[8]
|
Pruneri, G., Lazzeroni, M., Bagnardi, V., et al. (2017) The Prevalence and Clinical Relevance of Tumor-Infiltrating Lymphocytes (TILs) in Ductal Carcinoma in Situ of the Breast. Annals of Oncology, 28, 321-328. https://doi.org/10.1093/annonc/mdw623
|
[9]
|
Pelekanou, V., Carvajal-Hausdorf, D.E., Altan, M., et al. (2017) Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance. Breast Cancer Research, 19, Article No. 91. https://doi.org/10.1186/s13058-017-0884-8
|
[10]
|
Hamy, A.S., Bonsang-Kitzis, H., De Croze, D., et al. (2019) Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Clinical Cancer Research, 25, 6731-6741. https://doi.org/10.1158/1078-0432.CCR-18-3017
|
[11]
|
Stanton, S.E., Adams, S. and Disis, M.L. (2016) Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncology, 2, 1354-1360. https://doi.org/10.1001/jamaoncol.2016.1061
|
[12]
|
Li, S., Zhang, Y., Zhang, P., et al. (2022) Predictive and Prognostic Values of Tumor Infiltrating Lymphocytes in Breast Cancers Treated with Neoadjuvant Chemotherapy: A Meta-Analysis. Breast, 66, 97-109. https://doi.org/10.1016/j.breast.2022.10.001
|
[13]
|
Gao, G., Wang, Z., Qu, X., et al. (2020) Prognostic Value of Tumor-Infiltrating Lymphocytes in Patients with Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. BMC Cancer, 20, Article No. 179. https://doi.org/10.1186/s12885-020-6668-z
|
[14]
|
Loi, S., Drubay, D., Adams, S., et al. (2019) Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 37, 559-569. https://doi.org/10.1200/JCO.18.01010
|
[15]
|
Mangia, A., Saponaro, C., Vagheggini, A., et al. (2019) Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients? Cancers, 11, Article 1393. https://doi.org/10.3390/cancers11091393
|
[16]
|
黄婉莹, 杨向红. 三阴性乳腺癌中PD-1、PD-L1的表达与肿瘤浸润性淋巴细胞及临床病理指标的相关性[J]. 现代肿瘤医学, 2022, 30(12): 2181-2185.
|
[17]
|
范姣. 雄激素受体与肿瘤浸润性淋巴细胞对三阴性乳腺癌预后影响的相关性分析[D]: [硕士学位论文]. 大连: 大连医科大学, 2021.
|
[18]
|
Park, J.H., Jonas, S.F., Bataillon, G., et al. (2019) Prognostic Value of Tumor-Infiltrating Lymphocytes in Patients with Early-Stage Triple-Negative Breast Cancers (TNBC) Who Did Not Receive Adjuvant Chemotherapy. Annals of Oncology, 30, 1941-1949. https://doi.org/10.1093/annonc/mdz395
|
[19]
|
Kumar, A., Watkins, R. and Vilgelm, A.E. (2021) Cell Therapy with TILs: Training and Taming T Cells to Fight Cancer. Frontiers in Immunology, 12, Article 690499. https://doi.org/10.3389/fimmu.2021.690499
|
[20]
|
Lee, H., Lee, M., Seo, J.H., et al. (2020) Changes in Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer. Anticancer Research, 40, 1883-1890. https://doi.org/10.21873/anticanres.14142
|
[21]
|
Luen, S.J., Salgado, R., Dieci, M.V., et al. (2019) Prognostic Implications of Residual Disease Tumor-Infiltrating Lymphocytes and Residual Cancer Burden in Triple-Negative Breast Cancer Patients after Neoadjuvant Chemotherapy. Annals of Oncology, 30, 236-242. https://doi.org/10.1093/annonc/mdy547
|
[22]
|
Kochi, M., Iwamoto, T., Niikura, N., et al. (2017) Tumour-Infiltrating Lymphocytes (TILs)-Related Genomic Signature Predicts Chemotherapy Response in Breast Cancer. Breast Cancer Research and Treatment, 167, 39-47. https://doi.org/10.1007/s10549-017-4502-3
|
[23]
|
Loi, S., Sirtaine, N., Piette, F., et al. (2013) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31, 860-867. https://doi.org/10.1200/JCO.2011.41.0902
|
[24]
|
Loi, S., Michiels, S., Salgado, R., et al. (2014) Tumor Infiltrating Lymphocytes Are Prognostic in Triple Negative Breast Cancer and Predictive for Trastuzumab Benefit in Early Breast Cancer: Results from the FinHER Trial. Annals of Oncology, 25, 1544-1550. https://doi.org/10.1093/annonc/mdu112
|
[25]
|
Ingold Heppner, B., Untch, M., Denkert, C., et al. (2016) Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 22, 5747-5754. https://doi.org/10.1158/1078-0432.CCR-15-2338
|
[26]
|
Salgado, R., Denkert, C., Campbell, C., et al. (2015) Tumor-Infiltrating Lymphocytes and Associations with Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncology, 1, 448-455. https://doi.org/10.1001/jamaoncol.2015.0830
|
[27]
|
Liu, S., Mou, E., Zeng, S., et al. (2020) Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes. Cancer Management and Research, 12, 3145-3153. https://doi.org/10.2147/CMAR.S248071
|
[28]
|
Schmid, P., Rugo, H.S., Adams, S., et al. (2020) Atezolizumab plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 44-59. https://doi.org/10.1016/S1470-2045(19)30689-8
|
[29]
|
García-Torralba, E., Pérez Ramos, M., Ivars Rubio, A., et al. (2023) Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (STIL) in Early Luminal B Breast Cancer. Cancers, 15, Article 2846. https://doi.org/10.3390/cancers15102846
|
[30]
|
Makhlouf, S., Wahab, N., Toss, M., et al. (2023) Evaluation of Tumour Infiltrating Lymphocytes in Luminal Breast Cancer Using Artificial Intelligence. British Journal of Cancer, 129, 1747-1758. https://doi.org/10.1038/s41416-023-02451-3
|
[31]
|
Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172. https://doi.org/10.1016/S0140-6736(13)62422-8
|
[32]
|
Ingold Heppner, B., Untch, M., Denkert, C., et al. (2016) Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 22, 5747-5754. https://doi.org/10.1158/1078-0432.CCR-15-2338
|
[33]
|
Adams, S., Gray, R.J., Demaria, S., et al. (2014) Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers from Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 32, 2959-2966. https://doi.org/10.1200/JCO.2013.55.0491
|